New combination treatment shrinks tumours in pancreatic cancer
In an early study, more than six in ten patients responded to daraxonrasib plus chemotherapy, but there was no comparison group.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
A daily pill combined with chemotherapy shrank tumours in around six in ten participants with metastatic pancreatic cancer. The results come from an early phase I/II study involving 61 patients and still need to be confirmed in a larger comparative study.
The treatment consists of daraxonrasib, a drug intended to block certain KRAS mutations, together with gemcitabine and nab-paclitaxel. In the study, 61 patients with metastatic pancreatic cancer received the combination. About 61 per cent had an objective tumour response.
According to reports on the study results, five tumours were no longer visible on scans. In almost all participants, the tumours did not grow further for a period of time. Such outcomes are relevant in a disease that is often diagnosed only at a late stage and for which treatment options are limited.
The results do not, however, prove that the combination treatment works for all patients or cures the disease. The study had no control group with which the combination could be directly compared with standard treatment. The number of participants is also small, and the results are from early research.
Daraxonrasib targets KRAS, a protein involved in uncontrolled growth in many pancreatic tumours. Not every tumour has the same mutation, and biological activity in the laboratory does not automatically mean that patients will benefit from it in the long term. The duration of the response and the eventual survival benefit must therefore be established in follow-up research.
The results were presented on 20 November at an oncology conference in Barcelona. The researchers are working on follow-up studies, including a phase III trial. Until then, the main significance of the news is that the combination showed activity in metastatic disease in a small early study. It is still too soon to describe the treatment as a breakthrough or a new standard of care.
Also show where in Europe and in the world
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The study size, response rate and absence of a control group were confirmed by the sources used. The text limits the medical significance to early research results.
- confirmed The study included 61 patients with metastatic pancreatic cancer. — Number cited in reports and conference information. source
- confirmed About 61 per cent had an objective tumour response. — Result from the reported phase I/II data. source
- confirmed The study had no control group. — The reports used describe the research as an early phase I/II study without a comparison arm. source
- confirmed Five tumours were no longer visible on scans. — Number cited in reports on the trial. source
Editor's note
The results are recent and have been described by multiple sources, but come from a small early study without a control group. There is no basis for presenting this as a cure or standard treatment.Sources
- Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ — The Guardian
- Daily pill combined with chemotherapy shrinks tumors in early trial — Anadolu Agency
- Revolution Medicines presents updated Phase 1/2 data — Revolution Medicines